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Abstract
Background—Anxiety is highly prevalent among patients with coronary heart disease (CHD), 
and there is growing evidence that high levels of anxiety are associated with worse prognosis. 
However, few studies have evaluated the efficacy of treating anxiety in CHD patients for reducing 
symptoms and improving clinical outcomes. Exercise and selective serotonin reuptake inhibitors 
have been shown to be effective in treating patients with depression, but have not been studied in 
cardiac patients with high anxiety.
Methods—The UNWIND trial is a randomized clinical trial of patients with CHD who are at 
increased risk for adverse events because of comorbid anxiety. One hundred fifty participants with 
CHD and elevated anxiety symptoms and/or with a diagnosed anxiety disorder will be randomly 
assigned to 12 weeks of aerobic exercise (3×/wk, 35 min, 70–85% VO2peak), escitalopram (5–20 
mg qd), or placebo. Before and after 12 weeks of treatment, participants will undergo assessments 
of anxiety symptoms and CHD biomarkers of risk, including measures of inflammation, lipids, 
hemoglobin A1c, heart rate variability, and vascular endothelial function. Primary outcomes 
include post-intervention effects on symptoms of anxiety and CHD biomarkers. Secondary 
outcomes include clinical outcomes (cardiovascular hospitalizations and all-cause death) and 
measures of quality of life.
Conclusions—The UNWIND trial (ClinicalTrials.gov NCT02516332) will evaluate the efficacy 
of aerobic exercise and escitalopram for improving anxiety symptoms and reducing risk for 
adverse clinical events in anxious CHD patients.
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INTRODUCTION
Coronary heart disease (CHD) and anxiety disorders are both debilitating conditions that 
often co-exist and are associated with increased mortality, morbidity, and health care costs. 
CHD is a leading cause of mortality in the United States in men and women of every major 
ethnic group, affecting 370 million people annually
1
 at an estimated economic cost of 
$139.6 billion in both direct medical expenses and lost productivity
2
. Additionally, CHD 
may result in impaired quality of life and psychiatric comorbidity, including mood and 
anxiety disorders.
Anxiety disorders are the most commonly diagnosed form of mental illness and are 
responsible for one-third of the total expenditures for mental illness in the United States.
3 
Approximately half of those expenditures are due to the repeated use of health care services, 
since persons with anxiety disorders often solicit medical evaluation for symptoms that 
resemble physical illnesses. Data from the National Comorbidity Study-Replication suggest 
that the lifetime prevalence of any anxiety disorder is approximately one in three, more than 
any other psychiatric diagnostic category,
4
 and the prevalence of anxiety disorders has 
increased significantly over the past 2 decades.
5
Although the precise prevalence of anxiety disorders among cardiac patients has not been 
established, it has been estimated that 11–14% of cardiac patients suffer from generalized 
anxiety disorder (GAD)
6
 and over 40% of patients with stable CHD may have elevated 
anxiety symptoms.
7
 While elevated anxiety symptoms are a criterion common to all anxiety 
disorders, diagnostic criteria can be quite heterogeneous. In addition to diagnosed anxiety 
disorders, subsyndromal anxiety symptoms also can impair individuals’ psychosocial 
functioning and can increase health care resource utilization.
8
 Anxiety represents a risk 
factor for lower health-related quality of life,
9
 increased risk of all-cause mortality,
10
 and a 
variety of physical health problems, including CHD.
Prognostic Importance of Anxiety
A number of studies have shown a prospective relationship between depression and adverse 
outcomes, prompting the American Heart Association to recommend depression as a risk 
factor for patients with CHD.
11
 Although less widely studied, anxiety is increasingly 
considered also to have important prognostic significance in CHD patients. A number of 
studies, albeit not all studies
12–14, have found that elevated anxiety symptoms are associated 
with an increased mortality risk. For example, CHD patients with elevated anxiety assessed 
during hospitalization for cardiac catheterization showed a 2-fold increased risk of mortality, 
and this risk was independent of other predictors of risk, including depression.
10
 Similar 
findings have been reported by Frasure-Smith and colleagues who found that CHD patients 
with GAD assessed two months following hospital discharge for acute coronary syndrome 
showed a 2.3-fold increased risk of adverse cardiac events.
7
 Strik et al.
15
 reported a 2.8 fold 
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increased risk of adverse events in acute post-MI patients in which anxiety was measured 
one month following hospital discharge. Similarly, a 2-fold increased risk of adverse events 
was found in patients with stable CHD undergoing cardiac rehabilitation
16
 and in patients 
with elevated anxiety during annual clinic visits;
17
 and patients with elevated anxiety 
symptoms in the coronary care unit were found to exhibit greater mortality within the first 
year post-AMI.
18
Despite this evidence for a relationship between anxiety and adverse outcomes in CHD 
patients, the value of reducing anxiety in cardiac patients has not been established because 
of limited data from randomized control trials (RCTs) and a lack of evidence that treatment 
could improve clinical outcomes.
Pharmacologic Treatment for Anxiety
Many pharmacologic agents have been developed for treating different types of anxiety 
disorders, including barbiturates and benzodiazepines, azapirones (e.g., buspirone), 
tricyclics, selective serotonin reuptake inhibitors (SSRIs), and serotonin and norepinephrine 
reuptake inhibitors (SNRIs).
19
 SNRIs block the reuptake pump systems of serotonin and 
norepinephrine, inhibiting the reuptake of these neurotransmitters into the presynaptic 
neuron; SNRIs have a latency period of 2–4 weeks and low risk of dependency.
19
 The 
positive profile of SNRIs has led to the FDA approval of duloxetine for GAD
20
 and 
venlafaxine for GAD and social anxiety disorder (SAD).
21
 SSRIs block the reuptake of 
serotonin into the presynaptic neuron, and have a latency and risk profile similar to SNRIs. 
Further, SSRIs have proven to be effective for GAD, SAD, and panic disorder, thus multiple 
SSRIs have received FDA approval: paroxetine is approved for panic disorder, SAD, and 
GAD; sertraline is approved for SAD and panic disorder; fluoxetine is approved for panic 
disorder; and escitalopram is approved for GAD.
21
Although these compounds are effective for treating a variety of anxiety conditions, to our 
knowledge, no studies have reported the effects of treating anxiety on clinical outcomes in 
anxious cardiac patients. SSRIs have been studied in cardiac populations with depression 
with mixed results. For example, the SADHART study reported that sertraline produced 
greater improvements in depressive symptoms compared to placebo controls, but only in the 
subset of patients with more severe depression,
22
 and SADHART-CHF found no difference 
in depressive symptoms or clinical outcomes following treatment with sertraline compared 
to placebo in depressed patients with heart failure.
23
 In a non-randomized substudy from the 
ENRICHD trial, antidepressant medications were associated with reduced mortality.
24
 The 
CREATE trial reported that citalopram, when combined with clinical management, 
improved depression compared to placebo.
25
Several studies have examined the effects of escitalopram in depressed patients. MOOD-HF 
examined the effect of escitalopram on depression and anxiety in heart failure patients,
26
 but 
the study was stopped early due to ineffectiveness of the drug; changes in symptoms of 
anxiety were not reported.
27
 The DECARD study showed that escitalopram prevented 
depression
28
 and was well-tolerated in post-ACS patients.
29
 Finally, the REMIT study 
examined the effect of escitalopram in patients with stable CHD and evidence of mental-
stress induced myocardial ischemia. Although not the primary endpoint, scores on the 
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Spielberger State-Trait Anxiety Inventory (STAI)-State tended to decrease following 
treatment after adjusting for sex and baseline STAI-State scores.
30
 Because of the safety and 
tolerability of SSRIs in a cardiac population,
31
 their potential anxiolytic and anti-depressant 
effects, and the comorbidity between depression and anxiety, we believe that SSRIs, and 
specifically escitalopram, may be beneficial for treating anxiety in cardiac patients. To our 
knowledge, the UNWIND trial will be the first study to target cardiac patients with elevated 
anxiety using anxiolytic medication.
Exercise Treatment for Anxiety
There is growing evidence that exercise may have beneficial effects on anxiety. 
Epidemiological studies have observed an inverse relationship between exercise and anxiety. 
For example, Goodwin reported that persons who indicated they exercise “regularly” were at 
reduced risk for being diagnosed with an anxiety disorder compared to their sedentary 
counterparts (odds ratios from 0.64 to 0.78 for exercisers).
32
 In another study of 19,288 
participants in the Netherlands Twin Registry, individuals reporting 240 min a week of 
moderate exercise reported less anxiety and neuroticism compared with non-exercisers.
33 
Although encouraging, data from observational studies cannot prove that exercise was the 
cause of the reduced risk for an anxiety disorder; anxious persons also may be less likely to 
be physically active and engage in exercise.
There have been many exercise intervention trials with anxiety as an outcome, and while 
results have generally been positive, few studies have specifically targeted anxious 
individuals. For example, Wipfli and colleagues
34
 found that exercise was associated with an 
overall effect size of 0.48, indicating greater reductions in anxiety symptoms compared to 
no-treatment controls, and an effect size of 0.19 when exercise was compared to other 
established treatments for anxiety. In a review of 8 RCTs of patients with a broad range of 
anxiety disorders, Jayakody et al.
35
 noted that exercise seems to be effective as an adjunctive 
treatment for most anxiety disorders, but there were too few studies to provide meaningful 
conclusions. More recently, Stonerock et al.
36
 provided a comprehensive review of the 
literature on exercise and anxiety disorders. Examination of 12 RCTs suggested that the 
benefits of exercise were comparable to established psychiatric treatments and greater than 
placebo controls in select patient groups. However, most studies had significant 
methodological limitations, including small sample sizes, concurrent therapies, and 
inadequate assessment of adherence and fitness levels. Moreover, only two studies examined 
the anxiolytic effects of exercise in cardiac patients. One study reported more than a 69% 
reduction in anxiety among highly anxious participants in an exercise-based cardiac 
rehabilitation program
37
; however, there was no control group and exercise was only one 
component of the intervention. A second RCT that targeted cardiac patients with elevated 
anxiety reported greater reductions in symptoms of anxiety assessed by the STAI and the 
Profile of Mood States after 8 weeks of cardiac rehabilitation compared to community care 
controls.
38,39 However, the cardiac rehabilitation group also received concurrent weekly 90-
min group counseling sessions, so that the improvements could not be attributed to exercise 
training. Thus, while results from exercise studies are encouraging, the potential therapeutic 
benefits of exercise in CHD patients remain uncertain.
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UNWIND is a single-site, randomized clinical trial designed to evaluate whether aerobic 
exercise can reduce anxiety in CHD patients and, if so, how it compares to the currently 
prescribed anxiolytic medication escitalopram. In addition to the primary endpoint of 
anxiety, we also will examine the effects of aerobic exercise and/or escitalopram on an array 
of CHD biomarkers, including autonomic regulation, vascular function, and CHD blood 
markers (e.g., interleukin-6 [IL-6], high-sensitivity C-reactive protein [hsCRP], HbA1c, and 
insulin). These biomarkers were selected because of their prognostic significance and 
potential responsiveness to treatment.
Heart rate variability (HRV) is widely recognized as an important index of autonomic 
regulation of the heart and prognostic indicator of risk and will serve as our primary 
biomarker of interest. Reduced 24-hour HRV independently predicts mortality in community 
samples
40,41 and patients with CHD
42,43.
Baroreceptor reflex sensitivity (BRS) is also an index of cardiac regulation by the 
parasympathetic nervous system (PSNS), with experimental models showing that low levels 
of BRS predict sudden cardiac death (SCD) due to ventricular fibrillation.
44
 Anxiety has 
been linked to reduced PSNS control of heart rate in several different populations, including 
patients with anxiety disorders.
45,46 Elevated sympathetic nervous system (SNS) activity is 
another pathophysiological aspect of autonomic dysregulation contributing to the 
development of CHD that is thought to contribute to increased cardiovascular risk associated 
with anxiety.
47
 SSRIs appear to reduce HRV
48
, and there is evidence that regular exercise 
improves HRV, as well as BRS, in middle-aged and elderly sedentary subjects and patients 
with CHD.
49,50
Endothelial dysfunction plays a vital role in the development, progression, and clinical 
manifestations of atherosclerosis.
51,52 It has been related to a wide range of CHD risk 
factors, and has been shown to be prognostic in cardiac patients.
53
 Impaired FMD has been 
linked to elevated anxiety symptoms in CHD patients.
54
 Several small interventional studies 
have shown that FMD may be improved by exercise training in cardiac patients.
55,56
Inflammation is widely considered to play a central role in the development and progression 
of CHD. C-reactive protein (CRP) is a highly sensitive marker of underlying systemic 
inflammation.
57
 An elevated level of CRP is an independent risk factor for MI and 
stroke.
58,59 Interleukin-6 (IL-6) is an inflammatory cytokine that may be the initial event 
leading to an increase in CRP levels, and recent meta-analyses indicate that IL-6 may be 
more strongly related than CRP to the promotion of atherosclerosis.
60
 Pitsavos et al.
61 
observed a significant dose-response relationship between the severity of anxiety symptoms 
and CRP, and Frasure-Smith et al.
62
 reported that HRV was correlated with inflammatory 
markers and suggested that interventions targeting regulation of both autonomic control and 
inflammation may be especially worthwhile.
We hypothesize that both exercise training and escitalopram will reduce anxiety symptoms 
to a greater extent than placebo; exercise training will improve CHD biomarkers of risk, 
including autonomic regulation, vascular endothelial function, and inflammation, more than 
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either escitalopram or placebo; and improvements in CHD biomarkers will be mediated by 
reductions in symptoms of anxiety. We also will explore potential moderators of treatment 
(e.g., anxiety diagnoses, CHD severity) as well as the longer-term benefits of treatment by 
documenting medical events over a follow-up period of up to 4 years. The findings from this 
RCT will have important implications for anxiety assessment and management in CHD 
patients.
METHODS
One hundred fifty participants with CHD and anxiety will be randomized with 2:2:1 
allocation to 1 of 3 groups: (1) aerobic exercise (N = 60); (2) escitalopram (N = 60); or (3) 
placebo pill (N = 30). Participants will be evaluated on clinical, behavioral, and 
physiological dimensions at baseline and after a 12-week intervention. Assessments of 
anxiety, health behaviors, and quality of life also will be obtained 6- and 12-months post-
intervention. Additional measures of quality of life also will be obtained along with annual 
follow-up interviews to document clinical events. The study design is depicted in Figure 1. 
The study is registered at www.clinicaltrials.gov (ID: NCT02516332).
Participants
UNWIND will actively recruit women and minorities, with at least 50% women and 25% 
minorities.
Inclusion Criteria—Men and women age 40 years or older with documented CHD will be 
selected for study. Participants will have an anxiety symptom severity score of ≥8 (mild-
moderate) on the anxiety section of the Hospital Anxiety and Depression Scale (HADS-A) ; 
a subgroup of participants also will have a DSM-5 diagnosis of an Anxiety Disorder (See 
Table S1 for a more complete description). Because of the importance of treating debilitating 
symptoms and not merely psychiatric diagnoses,
63
 we will target patients with elevated 
symptoms of anxiety regardless of whether they meet diagnostic criteria for anxiety 
disorders.
Exclusion Criteria—Medical exclusions will include an MI or coronary revascularization 
procedure within the last 3 months, unstable angina, severe left ventricular dysfunction or 
decompensated heart failure, unrevascularized left main coronary artery stenosis >50%, and 
conditions that would preclude randomization to either escitalopram or exercise. Patients 
with a primary psychiatric diagnosis other than Anxiety Disorder will be excluded along 
with patients who are taking other medications that would preclude assignment to either 
drug or exercise conditions (e.g., clonidine, anticonvulsants, and MAO inhibitors).
Screening Procedures
All eligible participants will undergo a psychiatric screen to determine anxiety symptom 
severity and a medical screen to verify safe participation in any treatment group.
Psychiatric Screen—The Anxiety and Depression Detector (ADD)
64
 and the Patient 
Health Questionnaire (PHQ-9)
65
 will be used to screen for anxiety and depression symptom 
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severity. The ADD is a 5-item instrument that has been used to detect anxiety (and 
depression) in medical settings and is an effective screening tool for anxiety disorders (e.g., 
panic disorder, social phobia, and GAD). It is an established overall measure of distress and 
is likely to reflect a diagnosis of at least one of these conditions or significantly elevated 
levels of anxiety. Participants must obtain a score of ≥1; the ADD is correlated with the 
Overall Anxiety Severity and Impairment Scale,
66
 which also has been used to detect the 
presence of significant anxiety. The PHQ-9 is a brief, reliable, and valid measure of 
depression severity, which will be used to examine the comorbidity between anxiety and 
depression in participants.
Medical Screen—Each participant will receive a screening physical examination to assess 
blood pressure, routine blood tests, including metabolic and lipid panels, insulin, and 
HbA1c, health behaviors, including smoking and alcohol use, and presence of significant 
cognitive impairment.
Treatment Conditions
Participants will be randomly assigned to 1 of the 3 treatment conditions for 12 weeks. 
Randomization will occur after each subject has completed the assessment protocol and will 
adhere to standard procedures for randomized clinical trials.
67
 Participants will be stratified 
by sex (male/female), history of myocardial infarction (yes/no), diagnosed anxiety disorder 
(yes/no), and age (<60/≥60 years).
Aerobic Exercise—Participants will exercise three times per week under medical 
supervision at a designated cardiac rehabilitation facility. Exercise intensity will be at a level 
of 70–85% of VO2 peak as determined at the time of the baseline exercise treadmill test. 
Each exercise session will consist of 10 min of gradual warm-up exercises followed by 35 
min of continuous walking, biking, or jogging at the target intensity, and 5 min of cool down 
exercises for a total a 50 min.
Escitalopram/Placebo Pill—Treatment in the escitalopram and placebo pill arms will 
involve the same protocol. Subjects will have regular face-to-face visits and phone contact 
with a prescribing psychiatrist, who will be blinded to treatment condition. Participants will 
start on 5 mg once per day of either escitalopram or placebo. Daily doses will be titrated to 
10 mg at week 2 and to 15 mg or placebo equivalent at week 3 if there is no change or only 
minimal improvement in anxiety. At week 4, if there is no change or only minimal 
improvement in anxiety, and no or minimal side effects, a maximum daily dose of 20 mg or 
placebo equivalent will be prescribed. Supportive measures will be used to help manage 
medication side effects, and in such cases, doses may be decreased. Further, the STAI-State 
will be assessed weekly to assess changes in symptoms and determine the rate of change in 
anxiety symptoms over the course of the trial.
Assessments
Anxiety—Anxiety diagnosis will be assessed by structured clinical interviews. A clinical 
psychologist will administer modules from the Structured Clinical Interview for DSM-5 
Disorders (SCID)
68
 and the 14-item Hamilton Anxiety Rating Scale (HAMA)
69
. The 
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primary outcome measure will be scores on the HADS-A.
70
 Other psychiatric self-report 
anxiety assessments will include the Anxiety Sensitivity Index (ASI),
71
 the General Anxiety 
Disorder 7-item questionnaire (GAD-7),
72
 and the STAI-Trait.
73
 The STAI-State will be 
used to assess ongoing treatment response during the 12-week intervention.
Ancillary Self-Report Measures—Because symptoms of depression are likely to 
coexist with anxiety and major depressive disorder is an exclusion criterion, depressive 
symptoms will be assessed with the Beck Depression Inventory-II (BDI-II).
74
 Together, 
these assessments will afford a comprehensive analysis of each participant’s severity of 
anxiety symptoms and the comorbidity with depression.
In addition to measuring anxiety and depression, areas considered to reflect quality of life 








 self-efficacy, and perceived social support.
79,80 Further, we will assess a number 
of health behaviors that may affect participants’ health including the Godin Leisure-Time 
Exercise questionnaire
81
 to evaluate exercise habits, the Pittsburgh sleep questionnaire
82
 to 
examine sleep patterns, the Morisky Medication Adherence Scale
83
 to document medication 
adherence, and a dietary habits questionnaire
84
 to examine nutrition habits.
CHD Biomarkers—We will assess autonomic regulation by measuring heart rate 
variability (HRV) and baroreflex sensitivity (BRS), vascular endothelial function by 
measuring flow-mediated dilation (FMD) of the brachial artery, and a panel of CHD blood 
markers including measures of inflammation (hsCRP and IL-6), lipids (total cholesterol, 
HDL-, LDL-, and VLDL-cholesterol), and metabolic markers (glucose, insulin, and 
HbA1c). Further, to assess biologic markers of stress, urine samples will be collected over a 
24-hour period, and will be assayed for norepinephrine, epinephrine, and creatinine.
Physical Activity—Graded treadmill exercise testing will be conducted at baseline and at 
the conclusion of treatment to evaluate functional capacity. To obtain a measure of average 
daily physical activity, a 3-axis wrist accelerometer (Actigraph™) will be worn for 7 
continuous days. These clinical, biological, and psychometric measures will be completed 
by participants at both pre- and post-treatment assessments. Supplementary Table S1 
provides a detailed description of the measures to be obtained in the UNWIND study.
Follow-up
Participants will be followed up at 6- and 12-months post-randomization (i.e. 3 and 9 
months after completion of the 3-month intervention). At the 6-month follow-up, 
participants will receive assessments for anxiety and quality of life, and they will report 
exercise habits, any psychiatric treatments, psychopharmacologic medications, and medical 
events. At the 12-month follow-up, anxiety will be evaluated by the HADS-A and medical 
events will be reported. At both follow-up visits, participants will be queried as to whether 
they participated in any supplemental programs to reduce anxiety, including other 
medications and exercise. This naturalistic follow-up has been used in prior work
85–87 and 
yields important information regarding maintenance of lifestyle habits over time, which will 
be used to help interpret any group differences in anxiety and cardiovascular biomarkers 
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after 1 year. We also will document a number of clinical end points, including all-cause 
mortality, cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary 
revascularization, and hospitalization for angina or heart failure during annual follow-up 
examinations for up to 5 years. The schedule for the assessments is presented in Table 1.
Data analysis
The basic analytic strategy is a linear model carried out in the MPlus modeling software,
88 
with treatment group contrasts as factors, and ethnicity, age, sex, and pre-treatment measure 
of the outcome variable as the adjustment covariables. The intent-to-treat principle will be 
followed in all models, using full information maximum likelihood available in MPlus to 
manage missing data. For the case of the primary outcome, HADS-A, the model will include 
post-treatment HADS-A score as the response, with the predictors including two planned 
contrast variables representing 1) the two active treatments (exercise and escitalopram) vs. 
placebo and 2) exercise vs. escitalopram, with ethnicity, sex, age, and pre-treatment level of 
the HADS-A as the adjustment covariables. The primary biomarker outcome, HRV, will be 
evaluated similarly.
In addition to treatment effects, we will test the hypothesis that pre- to post-treatment change 
in HADS-A scores will mediate the improvements in intermediate CHD biomarkers. We 
also will explore possible treatment-specific mediators (e.g., change in VO2 mediating 
change in HRV for the Exercise group). We will explore possible moderators of the 
treatment effect using interaction terms including sex, race, participant expectations, age, 
and initial severity of anxiety (e.g., DSM-5 diagnosis for an Anxiety Disorder).
Power Analysis—The primary effect of interest is the treatment group difference on 
anxiety as measured by HADS-A scores. Power and sample size were estimated under the 
following assumptions: an alpha of .05, a linear model with age, sex, ethnicity, and baseline 
HADS-A score as covariates, a conservative estimate of the R-squared of .20 for the full 
model predicting post-treatment HADS-A, a 15% attrition rate, and two planned contrasts: 
active treatment vs. placebo and exercise vs. escitalopram. The comparison of primary 
interest will be active treatments vs. placebo. We estimate that a sample size of 150 (127 
after attrition) will yield .80 power to detect at least a .45 SD difference between the active 
treatments and Placebo. In the general linear model, the exercise vs. escitalopram test will be 
only slightly less powered in being able to detect a .50 SD difference.
Funding source
The study is supported by a grant (HL125522) from the National Heart, Lung, and Blood 
Institute. The authors are solely responsible for the design and conduct of this study, all 
study analyses, the drafting and editing of the manuscript, and its final contents.
DISCUSSION
Despite the prevalence and prognostic significance of anxiety in CHD populations, there 
have been few RCTs specifically targeting anxious CHD patients. Moreover, most of the 
previous studies have significant methodological limitations. A previous systematic review 
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 revealed that limitations include appropriate control groups, adequate sample 
size, blinding of assessors, monitoring of exercise adherence and volume, documentation of 
aerobic training effects, and selection of well-validated instruments to assess anxiety before 
and after treatment. UNWIND improves upon these methodologic limitations by providing 
well-validated anxiety assessments both pre- and post-intervention, wherein the assessments 
will be both self-report and clinician interview; using a prescribed exercise program in 
which exercise will be supervised and cardiorespiratory fitness changes will be measured by 
expired gas analyses; and assessors blinded to participants’ treatment group assignment. We 
also will examine potential mechanisms by which exercise and escitalopram may reduce 
anxiety and improve autonomic regulation, vascular function, and inflammatory markers.
SSRIs have been used safely for the treatment of clinical depression in cardiac patients, with 
equivocal efficacy. While SSRIs have been shown to be effective in treating anxiety in non-
CHD populations, to our knowledge there have been no RCTs examining the efficacy of 
SSRIs for treating anxiety in CHD patients. Because some cardiac patients may be reluctant 
to take additional medications, and psychotropic medications may not be effective for 
everyone or may produce unwanted side effects, there continues to be a need to identify 
alternative approaches for treating anxiety in cardiac patients. Evidence suggests that 
exercise may be one such approach,
36
 which we will evaluate in the UNWIND study.
Summary
UNWIND will examine the impact of a 12-week intervention of exercise, escitalopram, or 
placebo on anxiety symptoms and CHD biomarkers among individuals with cardiac disease 
and elevated anxiety. We hypothesize that: (1) Both exercise training and escitalopram will 
reduce anxiety symptoms to a greater extent than placebo; (2) Exercise training will improve 
CHD biomarkers of risk, including autonomic regulation, vascular endothelial function, and 
inflammation, more than escitalopram or placebo; and (3) Improvements in CHD 
biomarkers will be mediated by reductions in symptoms of anxiety. We also will explore 
potential moderators of treatment (e.g., specific anxiety diagnoses, sex, and race) as well as 
the longer-term benefits of treatment by documenting medical events over a follow-up 
period of up to 4 years. The results of UNWIND will inform patients, providers, and policy 
makers in judging whether exercise may be an effective treatment option for cardiac patients 
with elevated anxiety.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study Design
Figure 1 depicts the study design.
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